FeesSafety
Pluang+

Evaxion refocuses on cancer vaccines, reports Q3 2026 loss but extends cash runway to end 2027

Company Fundamentals
19 Nov 2026, 14:00 WIB
GlobeNewsWire
View Source
Bullish
Evaxion refocuses on cancer vaccines, reports Q3 2026 loss but extends cash runway to end 2027

Evaxion, a clinical-stage TechBio company, announced a strategic shift to prioritize immuno-oncology, focusing on personalized and off-the-shelf cancer vaccines using its AI-Immunology™ platform. The company reported a net loss of $3.5 million in Q3 2026 but extended its cash runway to the end of 2027 through equity sales. Key developments include promising phase 2 data for its personalized cancer vaccine EVX-01 and progress toward clinical trials for off-the-shelf vaccine EVX-04 targeting acute myeloid leukemia. Evaxion also won the 2026 International Prix Galien Award for its AI platform, reinforcing its technology's validation and partnership potential.

Evaxion's Q3 2026 financial update comes as 79 of 150 Health-sector US stocks on Pluang rose while 64 fell. For readers following Health stocks, here is Pluang's market snapshot as of Nov 19, 2026 18:12 WIB: Recursion Pharmaceuticals Inc (RXRX) traded at USD 2.92 with a 1-day change of +3.36% and a typical hold time of 23 days, with 63% of orders buying; ACADIA Pharmaceuticals Inc. (ACAD) was at USD 17.26, down 3.20%, held typically for 77 days, with all orders buying; and Nuwellis Inc (NUWE) at USD 3.95, up 3.13%, held for 34 days, also with all orders buying.

More News

Bath & Body Works beats earnings and revenue estimates, launches $500M buyback, raises sales outlook.

Bath & Body Works beats earnings and revenue estimates, launches $500M buyback, raises sales outlook.

Bath & Body Works reported third-quarter earnings per share of $0.26, surpassing the $0.12 estimate, and revenue of $1.58 billion, above the $1.55 billion estimate. The company also announced a new $500 million share repurchase program and raised its...

Company Fundamentals
Bullish
52 minutes ago
Pasqal integrates quantum processors natively into Slurm for easier HPC management with NVIDIA support.

Pasqal integrates quantum processors natively into Slurm for easier HPC management with NVIDIA support.

Pasqal has integrated its neutral-atom quantum processors natively into Slurm's Hierarchical Resources (HRES) system, recently expanded by NVIDIA. This allows supercomputing centers to manage quantum processing units (QPUs) alongside CPUs and GPUs mo...

Market News
Bullish
56 minutes ago
SpaceX shifts focus from satellite internet profits to rapid AI growth, trading at a high valuation.

SpaceX shifts focus from satellite internet profits to rapid AI growth, trading at a high valuation.

SpaceX currently earns most of its profits from its Starlink satellite internet service, which has 13.6 million subscribers and generated $2.37 billion in operating income last quarter. However, the company is aggressively pivoting towards artificial...

Market News
Bullish
1 hour ago
TSMC and Applied Materials poised for strong growth amid booming semiconductor demand.

TSMC and Applied Materials poised for strong growth amid booming semiconductor demand.

Despite a recent 25% drop in semiconductor stocks, TSMC and Applied Materials stand out due to their dominant market positions and growth potential. TSMC leads with a 73% share in the foundry market, benefiting from AI chip demand and planned price h...

Market News
Bullish
1 hour ago
Stock market faces sharp correction risk amid AI turmoil and rising interest rates, Buffett advises cautious investing.

Stock market faces sharp correction risk amid AI turmoil and rising interest rates, Buffett advises cautious investing.

The stock market is vulnerable to a sharp correction due to rising interest rates and uncertainty in the AI industry following Nvidia CEO Jensen Huang's departure amid scandal. Inflation pressures have led the Federal Reserve to raise rates, potentia...

Bearish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App